GUIDANT ACS Rx MULTI-LINK HAS 70% U.S. STENT MARKET DOLLAR VOLUME; EVEREST MEDICAL ATTRIBUTES 10% OF FOURTH-QUARTER VOLUME TO GUIDANT VASOVIEW BUSINESS
This article was originally published in The Gray Sheet
Executive Summary
Sales of Guidant's ACS Rx Multi-Link stent, launched on Oct. 2, topped $200 mil. in the fourth quarter of 1997, the company reported Feb. 3. According to Guidant President and CEO Ronald Dollens, who spoke the same day at a Piper Jaffray investor conference in New York City, the product now accounts for roughly 70% of the dollar volume and 60% of the unit volume of a U.S. stent market that is rapidly approaching an estimated $1 bil.
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.